Why the study?
Do activation peptide assays help predict the occurrence of thrombotic events in humans based on a new paradigm of arterial thrombosis?
Do activation peptide assays help predict the occurrence of thrombotic events in humans based on a new paradigm of arterial thrombosis?
This chapter reviews a new paradigm for arterial thrombosis driven by endothelial cell heterogeneity and the potential of activation peptide assays to predict thrombotic events.
Activation peptide assays require prospective validation before clinical use; leaves open whether endothelial heterogeneity paradigm advances thrombosis prediction.
This chapter summarizes the new paradigm for arterial thrombosis. This new paradigm emphasizes the heterogeneity of endothelial cells and the signaling pathways that control endothelial cell gene expression in surrounding tissue. It is suggested that genetic alterations in the signaling pathways are probably responsible for localized thrombosis, as manifested by heart attacks and strokes. A discussion of two clinical studies supporting the new arterial thrombosis paradigm is also included in this chapter. These studies, carried out by genetic engineering in mice, employ activation peptides to help predict the occurrence of thrombotic events in humans.
No takes yet. Share an insight, caveat, or question.
Robert Rosenberg (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: